TEL AVIV, Israel--(BUSINESS WIRE)--Sight Diagnostics Ⓡ, the company behind the first FDA-cleared direct-from-fingerstick Complete Blood Count (CBC) analyzer, announced today it has raised $71 million ...

Sight Diagnostics, an Israeli startup developing a machine-vision-based finger-prick analysis device, announced today $71 million in Series D funding. Koch Disruptive Technologies, Longliv Ventures ...

Sight Diagnostics has raised $71 million to help expand the commercial reach of its FDA-cleared, tabletop machine for analyzing a finger-prick’s worth of blood. The Tel Aviv-based company’s series D ...

Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More Sight Diagnostics, which is deploying an AI-powered blood analysis ...

Tel Aviv, Israel-based Sight Diagnostics, which makes a complete blood count (CBC) analyzer only requiring two drops of blood, announced Wednesday that it had raised $71 million in a Series D funding ...

TEL AVIV (Reuters) - Israel's Sight Diagnostics said on Wednesday it raised $71 million in private funding to expand sales of its finger-prick blood analyzer and support research and development. Koch ...

Due to the infamy of Theranos, even those not involved in the world of healthcare, know something about blood diagnostics and the effort to make it less burdensome. While the Theranos saga has burned ...

On August 5, blood-testing startup Sight Diagnostics raised another $71 million aimed at boosting its share of the $50 billion global market for complete blood count (CBC) testing — which doctors use ...